"KaloBios ended 2012 with a strong, differentiated clinical pipeline marked by three first-in-class, patient-targeted therapies for severe asthma, Pseudomonas infections associated with cystic fibrosis and pneumonia, and hematologic malignancies," said David Pritchard, KaloBios' President and Chief Executive Officer. "We continue to move forward aggressively to complete enrollment in the ongoing Phase 2 KB003 asthma study, our Phase 2 KB001-A cystic fibrosis (CF) study and our Phase 1 KB004 hematologic malignancy study."
Anticipated Upcoming Milestones for 2013-20142Q 2013:
File for Orphan Drug Status in the USA and European Union for KB001-A in CF3Q 2013:
Full recruitment of the KB003 asthma study3Q 2013:
Initiation of the expansion phase of the KB004 study in AML with EphA3 diagnostic test4Q 2013:
Full recruitment of the KB001-A CF study 1Q 2014:
Initiation of Phase 2 KB004 study in at least one new indication 1Q 2014:
Top line KB003 Phase 2 asthma study results2Q 2014:
Top line KB001-A CF study results3Q/4Q 2014:
Initiation of Sanofi Phase 2b study for prevention of ventilator-associated pneumonia (VAP) 4Q 2014:
Completion of enrollment in at least one hematologic malignancy indication in the expansion phase of KB004 About KaloBiosKaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.
Currently, KaloBios has three drug development programs:
|SOURCE KaloBios Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved